Company logo

CSL - CSL Limited

ASX -> Healthcare -> Biotechnology
Parkville, Australia
Type: Equity
CSL price evolution
CSL
(in millions $) 31 Dec 2023 30 Oct 2023 30 Jul 2023 1 May 2023
Current assets
Cash $1017 $1017 $1548 $1548
Short term investments
Net receivables $615.3 $768.1 $1040.4 $817.6
Inventory $361.7 $394.8 $599.2 $781.5
Total current assets $3408.1 $3657 $2692.9 $2152.3
Long term investments
Property, plant & equipment $705.6 $627.2 $798.8 $840.4
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $6620 $6816 $7176.2 $7115.4
Current liabilities
Accounts payable $245.5 $328.4 $397.2 $367
Deferred revenue
Short long term debt $1420 $1420 $1055 $1055
Total current liabilities $4718 $875.6 $1045.3 $930
Long term debt $10687 $2283.2 $2282.2 $2281.9
Total noncurrent liabilities
Total debt
Total liabilities $18142 $3892.2 $4144.2 $4057.1
Shareholders' equity
Retained earnings $5634 $5469.5 $5246.1 $5089.8
Other shareholder equity $2723 -$159 -$143.5 -$142.6
Total shareholder equity $19162 $19162 $17826 $17826
(in millions $) 30 Jun 2023 30 Jun 2022 30 Jun 2021 30 Jun 2020
Current assets
Cash $1548 $10436.4 $1808.8 $1194.4
Short term investments $4.8 $3.3
Net receivables $1936 $1513.1 $1648 $1593.3
Inventory $5466 $4333 $3780.6 $3509.5
Total current assets $9259 $16460.7 $7389.7 $6446.2
Long term investments $21.5 $14.2
Property, plant & equipment $9352 $8308.6 $7536 $6305.4
Goodwill & intangible assets
Total noncurrent assets $3657.1
Total investments
Total assets $36234 $28346 $18156.9 $15615.5
Current liabilities
Accounts payable $820 $591.8 $523 $458.3
Deferred revenue
Short long term debt $1055 $4494 $473.8 $202.3
Total current liabilities $4608 $7108.2 $3103.6 $2141.5
Long term debt $11172 $5163.8 $5333.1 $5790.5
Total noncurrent liabilities $2682.5
Total debt
Total liabilities $18408 $13768.5 $9775.6 $9087.9
Shareholders' equity
Retained earnings $14621 $13503.4 $12679.4 $11081
Other shareholder equity $2688 $590.3 -$4298.1 -$4553.4
Total shareholder equity $17826 $14577.5 $8381.3 $6527.6
(in millions $) 31 Jan 2024 30 Oct 2023 30 Jul 2023 1 May 2023
Revenue
Total revenue $1259.8 $1525.9 $1178.8
Cost of revenue
Gross Profit $466.1 $531.3 $350.8
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $166.2 $202.5 $201.6
Operating income
Income from continuing operations
EBIT
Income tax expense $66.6 $71.6 $28.4
Interest expense -$15.8 -$14.3 -$14.2
Net income
Net income $264.9 $194.6 $101.5
Income (for common shares)
(in millions $) 30 Jun 2023 30 Jun 2022 30 Jun 2021 30 Jun 2020
Revenue
Total revenue $13310 $10561.9 $10310 $9150.8
Cost of revenue $6466 $4829.6 $4466.7 $3924.4
Gross Profit $6844 $5732.3 $5843.3 $5226.4
Operating activities
Research & development $1235 $1156.2 $1001.4 $921.8
Selling, general & administrative $2356 $1608.7 $1616 $1588
Total operating expenses $10057 $7594.5 $7180 $6434.2
Operating income $3253 $2967.4 $3130 $2716.6
Income from continuing operations
EBIT
Income tax expense $419 $524.9 $588.1 $470.2
Interest expense -$410 -$178
Net income
Net income $2194 $2254.7 $2375 $2102.5
Income (for common shares) $2194 $2254.7 $2375 $2102.5
(in millions $) 31 Jan 2024 30 Oct 2023 30 Jul 2023 1 May 2023
Net income
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations
Investing activities
Capital expenditures
Investments
Total cash flows from investing $352.4 -$86.7 -$55.9 -$31.7
Financing activities
Dividends paid -$160.3 -$119.3 -$77.2 -$38.9
Sale and purchase of stock
Net borrowings
Total cash flows from financing -$1349.7 -$994.5 -$327.1 -$94.8
Effect of exchange rate $1.5 $0.8 $0.8
Change in cash and equivalents $205.5 -$268.8 -$11.5 $23.9
(in millions $) 30 Jun 2023 30 Jun 2022 30 Jun 2021 30 Jun 2020
Net income $2194 $2254.7 $2963.1 $2572.7
Operating activities
Depreciation $490 $448 $589.6 $419.8
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations $2601 $2628.7 $3621.9 $2488.3
Investing activities
Capital expenditures -$1228 -$1078.8 -$1667.1 -$1367.6
Investments
Total cash flows from investing -$11843 -$1636.1 -$1673.2 -$1366.7
Financing activities
Dividends paid -$1085 -$1038.7 -$958 -$883.1
Sale and purchase of stock $34 $4988.4 $56.4 $42
Net borrowings $1661 $3723.7 -$496.7 $198.8
Total cash flows from financing $456 $7675.9 -$1401.8 -$642.7
Effect of exchange rate -$22 $12.8 $31.9 $14.6
Change in cash and equivalents -$8825 $8604.3 $578.8 $493.5
News
CSL Limited (ASX:CSL) On An Uptrend: Could Fundamentals Be Driving The Stock?
Simply Wall St. via Yahoo Finance 2 Apr 2024
11 Best ASX Stocks To Buy Now
Insider Monkey via Yahoo Finance 24 Mar 2024
An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 21% Undervalued
Simply Wall St. via Yahoo Finance 25 Feb 2024
CSL's (ASX:CSL) investors will be pleased with their decent 60% return over the last five years
Simply Wall St. via Yahoo Finance 28 Jan 2024
New Strong Sell Stocks for November 15th
Zacks via Yahoo Finance 15 Nov 2023
CSL Limited's (ASX:CSL) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Simply Wall St. via Yahoo Finance 25 Oct 2023
Estimating The Intrinsic Value Of Carlisle Companies Incorporated (NYSE:CSL)
Simply Wall St. via Yahoo Finance 11 Oct 2023
Are Investors Undervaluing CSL Limited (ASX:CSL) By 31%?
Simply Wall St. via Yahoo Finance 18 Sep 2023
Investing in CSL (ASX:CSL) five years ago would have delivered you a 31% gain
Simply Wall St. via Yahoo Finance 18 Aug 2023
New Strong Sell Stocks for August 14th
Zacks via Yahoo Finance 14 Aug 2023
Fundamentals
Market cap $13.32B
Enterprise value N/A
Shares outstanding 47.70M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio 0.81
Book/Share 344.63
Cash/Share 21.32
EPS N/A
ROA N/A
ROE N/A
Debt/Equity 1.03
Net debt/EBITDA N/A
Current ratio 0.72
Quick ratio 0.65

Copyright Statfolio @ 2024

Social Accounts